Highlights PainReform Ltd.

Equities

PRFX

IL0011651580

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-04 pm EDT			5-day change	1st Jan Change
0.7001 ^USD	-0.74%		+1.83%	-74.54%

May. 15	PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	Apr. 16	MT
Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110	Apr. 09	CI
PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy	Apr. 02	CI
PainReform Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief	Jan. 03	CI
PainReform Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 15	CI
PainReform Ltd. Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File	23-09-11	CI
PainReform Ltd. Announces Selection for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary	23-09-07	CI
PainReform Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-10	CI
PainReform Regains Compliance With Nasdaq Listing Rule	23-07-19	MT
PainReform's Second Part of Phase 3 Trial of PRF-110 Faces Potential Delay	23-06-07	MT
PainReform Ltd. Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	23-06-07	CI
PainReform Ltd. Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	23-05-18	CI
PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
PainReform Ltd. Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery	23-05-01	CI
PainReform Ltd. Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery	23-03-28	CI
PainReform Ltd. Commences Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery	23-03-14	CI
PainReform : CONDENSED FINANCIAL STATEMENTS - Form 6-K	22-11-14	PU
PainReform Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PainReform Ltd.

Equities

PRFX

IL0011651580

Highlights

Filters